Dihexa 10mg
<h2What is Dihexa?</h2 <pDihexa (also known as PNB0408 or NhexanoylTyrIle(6)aminohexanoic amide) is a synthetic heptapeptide derived from angiotensin IV. It was developed by researchers at Washington State University and is among the most studied neuropeptides for its remarkable synaptogenic and neuroplastic properties in preclinical models.</p <pUnlike its parent molecule angiotensin IV, Dihexa has been engineered for enhanced metabolic stability and improved bloodbrain barrier penetration, making it a compelling research tool for investigating neurodegenerative and cognitive pathways.</p <h2Mechanism of Action</h2 <pDihexa exerts its effects primarily by binding with high affinity to hepatocyte growth factor (HGF) and potentiating its interaction with the cMet receptor tyrosine kinase. This HGF/cMet signaling cascade is a critical driver of dendritic spine formation, neuronal differentiation, neuroprotection against excitotoxic insults, and hippocampal neurogenesis in adult models.</p <pPreclinical studies have demonstrated that Dihexa is approximately 10<sup7</sup times more potent than brainderived neurotrophic factor (BDNF) in promoting synaptogenesis in vitro.</p <h2Preclinical Research Highlights</h2 <ul <li<strongCognitive function:</strong Rat models of scopolamineinduced cognitive impairment showed significant reversal of spatial memory deficits following Dihexa administration (McCoy et al., 2013, JPET).</li <li<strongSynaptogenesis:</strong In vitro hippocampal neuron cultures demonstrated a dosedependent increase in dendritic spine density and synaptic protein expression (PSD95, synaptophysin).</li <li<strongNeuroprotection:</strong Dihexa attenuated neuronal loss in models of ischemic brain injury by activating downstream PI3K/Akt and MAPK/ERK survival pathways via cMet.</li <li<strongAlzheimer's models:</strong Transgenic mouse models of amyloid pathology showed improved performance in Morris Water Maze and novel object recognition tasks.</li <li<strongBloodbrain barrier penetration:</strong Pharmacokinetic studies confirm oral and peripheral bioavailability with CNS distribution, attributed to its small molecular weight (504.67 g/mol) and lipophilic character.</li </ul <h2Product Specifications</h2 <table <tr<td<strongCAS Number</strong</td<td1401708835</td</tr <tr<td<strongMolecular Formula</strong</td<tdC₂₇H₄₄N₄O₅</td</tr <tr<td<strongMolecular Weight</strong</td<td504.67 g/mol</td</tr <tr<td<strongPurity</strong</td<td≥99% (HPLC verified)</td</tr <tr<td<strongForm</strong</td<tdLyophilized powder, 10mg vial</td</tr <tr<td<strongReconstitution</strong</td<tdDMSO or bacteriostatic water</td</tr <tr<td<strongStorage</strong</td<td−20°C longterm; 4°C shortterm (up to 4 weeks)</td</tr <tr<td<strongAppearance</strong</td<tdWhite to offwhite lyophilized powder</td</tr </table <p<strongFor laboratory research use only. Not for human or veterinary consumption.</strong</p Purity specification: ≥99% Purity (HPLC). CAS number: 1401708-83-5. Category: Nootropics & Cognitive.
For research use only. Not for human consumption.